Terns Pharmaceuticals to Participate in Upcoming Investor Conferences
19 Octubre 2023 - 3:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology, non-alcoholic steatohepatitis (NASH)
and obesity, today announced that members of management will be
participating in the following upcoming investor conferences:
H.C. Wainwright 7th
Annual NASH Virtual Investor ConferenceDate/Time:
Tuesday, October 24, 2023 at 2:30 PM ETFormat: Fireside
ChatLocation: Virtual
UBS Biopharma ConferenceDate/Time: Wednesday,
November 8, 2023 at 4:30 PM ETFormat: Fireside ChatLocation: Miami
Beach, FL
Live webcasts of the fireside chats will be available on the
investor relations page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com. A replay of the webcasts will be
archived on Terns’ website for at least 30 days following the
presentations.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to
address serious diseases, including oncology, NASH and obesity.
Terns’ pipeline includes two clinical stage development programs
including an allosteric BCR-ABL inhibitor and a THR-β agonist, and
preclinical small-molecule GLP-1 receptor agonist and GIPR
modulator programs. For more information, please visit:
www.ternspharma.com.
Contacts for Terns
InvestorsJustin Ng
investors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024